Health Care · Pharmaceutical Preparations

HROW HARROW, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1360214132 filings
Russell 2000

HROW at a glance

HARROW, INC. (HROW, SEC CIK 1360214) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), HARROW, INC. (HROW) reported revenue of $272.3 million (up 36.4% from FY2024) and a net loss of $5.1 million. Diluted EPS was -$0.14.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding HARROW, INC. (HROW) shares worth $265.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Shojaei Amir on August 14, 2026 of 11,250 shares at $40.00 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$272.3M
+36.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$265.4M · +0 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: U.S. ophthalmic disease management with FDA-approved branded pharmaceuticals and ophthalmology-focused pharmaceutical compounding
  • New product emphasis: Commercial launches planned for BYOOVIZ and BYQLOVI in mid-2026; OPUVIZ expected mid-2027; MELT-300 sedation tablet with FDA NDA filing expected H1 2027
  • Strategic shift: Full acquisition of Melt Pharmaceuticals in Nov 2025, integrating MELT-300 non-IV sedation program into Harrow's pipeline and consolidating R&D
  • Quantitative highlight: Ownership increased MELT to 100% via $4.3M upfront and contingent milestone payments; ImprimisRx serves 10,000+ U.S. eyecare prescribers
  • Noteworthy fact: MELT-300 poised as first FDA-approved non-opioid, sublingual sedation therapy targeting broad procedural sedation beyond ophthalmology

Risk Factors

  • Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025
  • Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025
  • Operational risk: Contract manufacturing commitments of $10.7M for 2026 with minimum annual order requirements
  • Competitive risk: ImprimisRx segment faces revenue decline from $83.5M in 2024 to $76.5M in 2025 amid competitive pressures
  • Financial risk: Customer concentration with two customers accounting for over 10% of Branded revenues in 2024 and 2025 affecting revenue stability

Management Discussion & Analysis

  • Revenue $272.3M up 36% YoY from $199.6M; IHEEZO sales $81.3M (+65% YoY), VEVYE sales $88.7M (+216% YoY), Other branded sales down $12.5M
  • Gross margin branded 81.0% vs 81.3% prior year, ImprimisRx margin 59.9% down from 67.0%, net loss narrowed to $5.1M from $17.5M
  • Best performing segment: Branded products revenue $195.8M up $79.6M; Worst: ImprimisRx revenue $76.5M down $7.0M
  • Operating cash flow positive $43.9M vs negative $22.2M prior year; Capex and acquisition spend $5.5M; Debt refinancing with $242.7M 8.625% notes issued, prior debt paid off
  • Management expanding commercial sales teams in 2026; pipeline growth supported by Melt acquisition, new product launches BYOOVIZ and BYQLOVI mid-2026; key risks include regulatory and reimbursement challenges

AI summary of the HROW 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $99.297M, up $27.659M YoY from $71.638M
  • Best performer VEVYE, revenue $39.699M, up $17.073M YoY
  • Worst performer compounding, revenue $15.835M, down $4.221M YoY
  • Branded gross margin 79.3% vs 81.6% YoY, compounding margin 55.2% vs 59.0%
  • Cash $75.336M at September 30, operating cash flow nine-month use $27.363M; $48.915M financing inflow from 2030 Notes
  • TYRVAYA expected to contribute over $30M revenue in 2027, with approximately $20M annual operating expenses; licensor discussions remain unresolved

Risk Factors

  • New risk: TYRVAYA acquisition triggered potential VEVYE license conflict, requiring divestiture or rights termination
  • Financial risk: Up to $70,000,000 in TYRVAYA contingent milestone payments may remain payable
  • Regulatory risk: Proposed CMS GLOBE and GUARD models could increase ophthalmic-product rebates using international benchmarks
  • Market risk: Payor step edits, prior authorization, and formulary restrictions could reduce reimbursed patient access
  • Reporting risk: Inaccurate rebate and chargeback estimates could reduce revenues, margins, and cash flows

AI summary of the HROW 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Corporate presentation furnished for investor conferences and meetings, signaling management’s current investor messaging
  • Presentation content in Exhibit 99.1 may contain strategic, operational, or financial updates relevant to valuation

Item EX-99.1: Item EX-99.1

  • Corporate presentation targets 2026 revenue of $350M-$365M, supported by Q3 revenue of $99.3M and $21.2M adjusted EBITDA
  • Q3 branded revenue $83.5M, 79.3% branded gross margin, with VEVYE, IHEEZO and TRIESENCE generating $75.7M
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 9, 2026
  • Stockholder letter includes updates on recent corporate developments

Item 7.01: Regulation FD Disclosure

  • Exhibit 99.3 contains Harrow’s investor presentation for earnings calls, conferences and management meetings
  • Presentation content may provide management’s latest business priorities and investor messaging

Item EX-99.2: Item EX-99.2

  • Q3 revenue $99.3M, up 39% YoY, led by branded products at $83.5M, up 62%
  • GAAP net income $9.8M included a $5.0M litigation settlement gain, limiting earnings quality

Item EX-99.1: Item EX-99.1

  • Q3 revenue $99.3M, up 39% YoY, led by branded revenue of $83.5M, approximately 84% of total revenue
  • GAAP net income $9.8M benefited from a $5.0M litigation settlement gain, while nine-month net loss reached $35.1M

Item EX-99.3: Item EX-99.3

  • Q3 revenue $99.3M, up 41% QoQ and 39% YoY, with adjusted EBITDA $21.2M, up 62% YoY
  • FY2026 revenue outlook reaffirmed at $350M-$365M, requiring implied Q4 revenue of $135.8M-$150.8M
Filed Oct 5, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights
  • Closing cash consideration fixed at $30.0 million, eliminating net working capital adjustment uncertainty

Item 2.01: Completion of Acquisition or Disposition of Assets

  • TYRVAYA rights acquired globally excluding Japan, including regulatory approvals, intellectual property, technology, inventory and contracts
  • $30.0 million upfront cash payment, funded from cash on hand, reducing liquidity

Item EX-99.1: Item EX-99.1

  • TYRVAYA acquisition closed for $30 million cash, with up to $70 million sales-based milestones, potential consideration $100 million
  • Worldwide rights acquired except Japan, with Viatris retaining Japan commercialization and paying Harrow royalties

Item 7.01: Regulation FD Disclosure

  • Harrow completed its acquisition of the Acquired Assets on October 5, 2026
  • Exhibit 99.1 contains the acquisition announcement and transaction details for investor review

AI summaries of HROW 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HROW

Don't miss the next HROW filing

  • Alerts as it files. A push when HROW files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HROW, by share count.
  • Ask anything. An AI agent that reads every HROW filing and answers with sources.

HROW alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Shojaei AmirMAug 14, 2026$35.96
Shojaei AmirMAug 14, 2026$35.96
Shojaei AmirSellAug 14, 2026$40.00
Graves Adrienne LAJun 18, 2026-
SILVERNAIL LAUREN PAJun 18, 2026-
Sternberg Perry J.AJun 18, 2026-
Graves Adrienne LBuyMay 18, 2026$31.07
SILVERNAIL LAUREN PBuyMay 18, 2026$31.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$199.6M$272.3M
Gross Profit-$150.4M$204.4M
Operating Income-$8.8M$30.5M
Net Income--$17.5M-$5.1M
Gross Margin-75.3%75.1%
Op. Margin-4.4%11.2%
Net Margin--8.8%-1.9%
Balance Sheet
Total Assets$312.2M$389.0M$399.5M
Equity$70.8M$69.7M$52.4M
ROE--25.1%-9.8%
Per Share
EPS-$-0.49$-0.14
Cash Flow
Operating CF--$22.2M$43.9M
CapEx-$1.6M$887K

Source: XBRL data in HARROW, INC. (HROW)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HROW share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HROW shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$265.4M
Q2 202627$323.9M
Q1 202626$252.2M
Q4 202525$383.7M
Q3 202525$365.8M
Q2 202524$247.9M
Q1 202520$136.9M
Q4 202416$164.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HROW filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KOct 5, 2026Analysis-
8-KSep 4, 2026Analysis-
4Aug 17, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
8-KAug 6, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 22, 2026Analysis-
8-KJun 3, 2026Analysis
4May 19, 2026-
4May 19, 2026-
4May 18, 2026-
8-KMay 11, 2026Analysis
10-QMay 11, 2026Analysis
8-KMar 27, 2026--
8-KMar 24, 2026--
8-KMar 24, 2026--
SC 13GMar 11, 2026-
8-KMar 10, 2026Analysis-
4Mar 5, 2026--

Related Health Care companies

All Health Care →

HROW SEC filings: frequently asked questions

Which institutions hold HROW stock?

As of September 30, 2026, the largest HARROW, INC. (HROW) holders among the 13F filers tracked by SignalX were BlackRock ($91.1 million), Vanguard Capital Management LLC ($43.0 million), State Street Corp ($31.6 million), Dimensional Fund Advisors ($22.2 million), Citadel Advisors LLC ($16.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HROW's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), HARROW, INC. (HROW) reported revenue of $272.3 million (up 36.4% from FY2024) and a net loss of $5.1 million. Diluted EPS was -$0.14. The figures come from the XBRL data in the 10-K.

What are the main risks in HROW's latest 10-K?

In the 10-K filed March 2, 2026, HARROW, INC. (HROW) flagged: Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025. Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025. (AI summary of the Risk Factors section.)

What did HROW report in its latest 8-K?

HARROW, INC. (HROW) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Corporate presentation furnished for investor conferences and meetings, signaling management’s current investor messaging.

What are the latest HROW SEC filings?

HARROW, INC. (HROW) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 17, 2026.

What is HROW's SEC CIK number?

HARROW, INC. (HROW)'s SEC Central Index Key (CIK) is 1360214. EDGAR lists every HROW filing under that number.

Ask anything about HROW

The research agent reads HROW's filings, financials, insider trades and 13F holders, then answers with sources.